PV Agreement definition

PV Agreement shall have the meaning set forth in Section 5.3.
PV Agreement means the pharmacovigilance agreement to be entered into by the Parties as provided in Section 3.15.
PV Agreement is defined in Section 2.7(a).

Examples of PV Agreement in a sentence

  • All rights, remedies, undertakings, obligations, and agreements contained in this PV Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation, or agreement of either Party.

  • The PV Agreement will govern the investigation of adverse experience reports and action to be taken with regards to Product-related adverse experience reports, such that each of the Parties can comply with its legal and regulatory obligations worldwide.

  • A waiver by either Party of any of the terms and conditions of this PV Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof.

  • The captions to this PV Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions hereof.

  • Information exchanged by the Parties pursuant to this PV Agreement can be transmitted by a secure internet-based interface, e-mail, facsimile, overnight courier, or any other means the Parties agree.


More Definitions of PV Agreement

PV Agreement is defined in Section 11.1.
PV Agreement means the First Amended and Restated Safety Agreement between Amgen Inc and GSK concerning the Collaboration Territory dated 15 July 2013.
PV Agreement means this Pharmacovigilance Agreement as amended under version control by the parties.
PV Agreement means the Lorcaserin Pharmacovigilance Agreement for the Exchange of Drug Safety Information, dated as of May 13, 2014, entered into by Eisai and Arena GmbH, as amended from time to time.
PV Agreement has the meaning set forth in the preamble hereto.
PV Agreement has the meaning set forth in Section 4.2.1.
PV Agreement means that certain Pharmacovigilance and Safety Data Exchange Agreement entered into between HGEN and Licensee prior to the earlier of (i) any use of the Licensed Product in humans (including without limitation for clinical trials) for the Licensed Indication in the Territory, or (ii) the date which is one hundred twenty (120) days after the date of the approval of a BLA for the Licensed Product in the U.S.